ArticleHelicobacter
Empirical Rescue Eradication Therapy for Helicobacter pylori Infection in Second and Subsequent Treatment Lines: Experience From 500 Cases of the Brazilian Registry on H. pylori Management (Hp-BrazilReg).
Article in Helicobacter. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tetracycline for Helicobacter pylori eradication: a narrative review from quadruple to dual therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- VTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors.
Funding
Abstract
backgroundThe effectiveness of anti-H. pylori treatment diminishes with therapy failure, making regional performance understanding crucial.
objectiveTo evaluate the effectiveness of empirical therapy in second-line and subsequent treatments in Brazil.
methodsA multicenter, prospective, noninterventional registry assessed H. pylori management outcomes by Brazilian gastroenterologists (Hp-BrazilRe, Hp-WorldReg's partner). Data were registered at e-CRF AEG-ReCap from March 2022 to October 2024 and analyzed via modified intention-to-treat (mITT) methodology. Data were subject to quality review.
results572 patients (mean age 52 years, 64% women) were included. The primary treatment indications were dyspepsia (64%) and gastroduodenal ulcer (9.2%). Among them, 67% underwent second-line therapy, while 33% received third-line or subsequent treatments. Proton-pump inhibitors (PPIs) were administered at low (40%), standard (10%), and high doses (24%), with vonoprazan used in 26% of cases. The overall eradication rate for second-line treatment was 74%, with the most common regimen being triple therapy (PPI + amoxicillin + levofloxacin), achieving 73% eradication for 14 days and 57% for 10 days. Adding bismuth to the 14-day regimen increased effectiveness to 100% (p = 0.016). In third-line therapy, a regimen of PPI-bismuth-tetracycline-metronidazole yielded an 87% cure rate. The fourth-line dual therapy with amoxicillin-vonoprazan achieved 100% eradication, while bismuth-quadruple therapy showed similar results. Dual therapy with vonoprazan and amoxicillin was also effective in fifth-line treatments, achieving 100% effectiveness. Mild adverse events occurred in 23% of patients, with nausea being the most common (14%), and compliance was 99%.
conclusionIn Brazil, the overall effectiveness of second-line therapy was suboptimal (< 90%); however, the combination of bismuth-amoxicillin-levofloxacin prescribed for 14 days reported successful cure rates. In the third-line, the classical bismuth-quadruple therapy with metronidazole-tetracycline provided acceptable results (87%). Alternatively, dual therapy with vonoprazan and amoxicillin and rifabutin-based bismuth-quadruple therapy showed promising results in third- and fifth-line rescue treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.